Your browser doesn't support javascript.
loading
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens, Anouk K M; Bos, Monique E M M; Lopez-Yurda, Marta; Bouma, Jeanette M; Rademaker-Lakhai, Jeany M; Honkoop, Aafke H; de Graaf, Hiltje; van Druten, Edith; van Warmerdam, Laurence J C; van der Sangen, Maurice J C; Tjan-Heijnen, Vivianne C G; Erdkamp, Frans L G.
Affiliation
  • Claessens AKM; Department of Medical Oncology, Zuyderland Medical Centre, Dr. H. van der Hoffplein 1, 6162 BG, Geleen, The Netherlands.
  • Bos MEMM; Department of Medical Oncology, Erasmus Medical Centre, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Lopez-Yurda M; Department of Biometrics, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Bouma JM; Department of Trial Registration, Comprehensive Cancer Centre the Netherlands, Vasteland 78, 3011 BN, Rotterdam, The Netherlands.
  • Rademaker-Lakhai JM; Dutch Breast Cancer Research Group, BOOG Study Centre, IJsbaanpad 9, 1076 CV, Amsterdam, The Netherlands.
  • Honkoop AH; Department of Medical Oncology, Isala Clinic, Dokter van Heesweg 2, 8025 AB, Zwolle, The Netherlands.
  • de Graaf H; Department of Medical Oncology, Leeuwarden Medical Centre, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands.
  • van Druten E; Department of Oncologic Research, Reinier de Graaf Hospital, Reinier de Graafweg 5, 8934 AD, Delft, The Netherlands.
  • van Warmerdam LJC; Department of Medical Oncology, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
  • van der Sangen MJC; Department of Medical Oncology, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
  • Tjan-Heijnen VCG; Department of Radiation Oncology, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
  • Erdkamp FLG; Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
Breast Cancer Res Treat ; 172(2): 413-423, 2018 Nov.
Article in En | MEDLINE | ID: mdl-30121808
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel / Receptor, ErbB-2 / Bevacizumab Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Breast Cancer Res Treat Year: 2018 Type: Article Affiliation country: Netherlands
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel / Receptor, ErbB-2 / Bevacizumab Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Breast Cancer Res Treat Year: 2018 Type: Article Affiliation country: Netherlands